 In the human endotoxemia model, intravenously administered endotoxin lipopolysaccharide LPS elicits a systemic immune response with release of pro-inflammatory cytokines, such as TNF α. This trial will determine if an anti-inflammatory effect can be produced by acute VNS using a minimally invasive delivery method. 